Frovatriptan

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Spielmann (Control mainly exposed other treatments, sick), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Pregnant women suffering from migraine disorder but not taking triptans between their last menstrual period and delivery.	19 / 475	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Spielmann (Control unexposed, disease free), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Frovatriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women without migraine disorder who were neither exposed to triptans nor to one of the following established teratogens or fetotoxicant.	19 / 1733	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.

Study	Country Study period	Case	Control	Sample size	Rmk